The global allergy diagnostic market is expected to grow from USD 6.80 billion in 2025 to USD 10.77 billion by 2030, at a CAGR of 9.6%. Growth is driven by technological innovations such as multiplex immunoassays and molecular allergology, rising allergy incidence, and increasing awareness. North America leads the market, with major players including Thermo Fisher Scientific, Siemens Healthineers, and Danaher Corporation dominating the competitive landscape.

The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.

The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

The global Pharmaceutical Microbiology QC Testing Market is projected to grow from USD 5.08 billion in 2025 to USD 17.65 billion by 2035, at a CAGR of 13.27%. Growth is driven by increased regulatory oversight, laboratory automation, antimicrobial resistance concerns, and adoption of advanced technologies like AI-enabled molecular platforms and MALDI-TOF mass spectrometry. North America leads with 39.12% market share, while Asia Pacific is expected to grow fastest at 14.33% CAGR.

The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.

The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.

The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share, payable on April 24, 2026 to shareholders of record on March 27, 2026.

Major M&A activity continues across multiple sectors: Starboard Value pushes TripAdvisor toward a sale, Hims & Hers acquires Eucalyptus for $1.15B to expand internationally, Danaher buys Masimo for $9.9B, Mister Car Wash goes private via Leonard Green for $3.1B, and Devon Energy completes a $21.4B merger with Coterra Energy. Meanwhile, Saks Global struggles with vendor shipments during bankruptcy, and Warner Bros. Discovery rejects Paramount's hostile bid.

Danaher agreed to acquire Masimo Corporation for $180 per share in an all-cash deal valued at $9.9 billion. The acquisition is expected to be accretive to earnings by $0.15-$0.20 in the first full year and approximately $0.70 by the fifth year, with projected annual synergies exceeding $175 million. Analysts view the deal as having sound financial rationale with strong recurring revenue and margin improvement potential.

Danaher Corp. is reportedly nearing a $9.9 billion acquisition of Masimo Corp., with an announcement potentially coming as early as Tuesday. The deal represents a significant premium to Masimo's $7 billion market cap and follows governance changes driven by activist investors. Masimo shares surged 34.51% on the news, while Danaher shares fell 5.22% in premarket trading.